2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 1535

Enhancing Patient Ability to Process and Use Information about Medication Risks and Benefits

Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

9:00AM-11:00AM: Abstract Number: 1196

Entheseal Involvement in Asymptomatic Healthy Subjects: Prevalence and Distribution of the Ultrasound Elementary Lesions of Enthesitis, with a Particular Focus on Those Indicating “Active” Inflammation

Imaging of Rheumatic Diseases Poster II: Ultrasound

9:00AM-11:00AM: Abstract Number: 1759

Eosinophilic Granulomatosis with Polyangiitis: A Monocentric Cohort Analysis of Manifestations and Relapses of ANCA-Positive and ANCA-Negative Patients

Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Abstract Number: 1124

Epidemiological Characteristics of Inpatient Admissions for Acute Inflammatory Gout Arthropathy and Factors Affecting Length of Stay: A National Level Study

Epidemiology and Public Health Poster II: Gout, Ankylosing Spondylitis, Osteoarthritis, Osteoporosis, Pain, and Function

9:00AM-11:00AM: Abstract Number: 1651

Epidemiology of Depression and Anxiety in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 992

Epigallocatechin-3-Gallate (EGCG) Suppresses Systemic Inflammation By Inhibiting IL-6-Induced STAT3 Activation in Cultured Hepatocytes and in Liver Tissue of Adjuvant-Induced Arthritis (AIA) Rats

Cytokines and Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 1403

Estimates of Minimally Important Differences and Patient Acceptable Symptom State in Five Patient-Reported Outcomes Measurement Information System Short-Forms Among Individuals with SLE

Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes

9:00AM-11:00AM: Abstract Number: 1153

EULAR ‘Points to Consider’ for the Conduction of Workforce Requirement Studies in Rheumatology

Epidemiology and Public Health Poster II: Gout, Ankylosing Spondylitis, Osteoarthritis, Osteoporosis, Pain, and Function

9:00AM-11:00AM: Abstract Number: 1278

Evaluating a Causal Role of Mitochondrial Variation in the Development of Gout

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 1382

Evaluating Results of an Interferon-γ Release Assay in Patients with Autoimmune Skin Disease on Hydroxychloroquine

Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes

9:00AM-11:00AM: Abstract Number: 1421

Evaluating the Validity of SIX-Minute Walk Test in Juvenile Systemic Sclerosis

Pediatric Rheumatology – Clinical Poster II: Autoinflammatory Disorders, Scleroderma, and Miscellaneous

9:00AM-11:00AM: Abstract Number: 1716

Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis in a Phase II Trial of Abatacept Vs. Placebo

Systemic Sclerosis and Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1677

Evaluation of Erythrocyte Sedimentation Rate As a Marker of Disease Activity in Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 1323

Evaluation of Prolidase and HIF-1α Levels in Patients with Familial Mediterranean Fever (FMF)

Miscellaneous Rheumatic and Inflammatory Diseases Poster II: Interstitial Lung Disease, Still's Disease, FMF, Polychondritis

9:00AM-11:00AM: Abstract Number: 1761

Evaluation of the Functional Activity of Endothelial Progenitor Cells in Patients with ANCA-Associated Vasculitis

Vasculitis – ANCA-Associated Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].